psychedelics investing Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
psychedelics investing Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
psychedelics investing Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
psychedelics investing Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
